Boehringer Ingelheim Corporation's Gilotrif Wins FDA OK for Advanced Lung Cancer

Published: Jul 15, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

The U.S. Food and Drug Administration approved a lung cancer drug made by Boehringer Ingelheim to treat patients who are suffering from late stage non-small cell lung cancer and whose tumors express a specific type of gene mutation. The drug, Gilotrif, was approved along with a companion diagnostic kit that can help determine if a patient's lung cancer cells express the epidermal growth factor receptor (EGFR) gene mutation.

Help employers find you! Check out all the jobs and post your resume.

Back to news